McKesson reports Q4 adjusted EPS $6.18, consensus $6.34

Reports Q4 revenue $76.4B, consensus $79.32B. “McKesson reported fourth quarter results, marking the close to a strong fiscal 2024, underpinned by continued momentum across the enterprise,” said CEO Brian Tyler. “The results underscore the execution against our company priorities, differentiated capabilities within the oncology and biopharma services platforms, and the sustained strength of our core distribution businesses. We continue to leverage the breadth and depth of our assets, delivering meaningful outcomes for our customers, partners, patients, and communities. I want to thank all McKesson employees for their efforts, dedication, and contributions.”